Cargando…

Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature

BACKGROUND: Anti-tumor necrosis factor agents were the first biologic therapy approved for the management of Crohn's disease (CD). Heart failure (HF) is a rare but potential adverse effect of these medications. The objective of this report is to describe a patient with CD who developed HF after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grillo, Thais Gagno, Almeida, Luciana Rocha, Beraldo, Rodrigo Fedatto, Marcondes, Mariana Barros, Queiróz, Diego Aparecido Rios, da Silva, Daniel Luiz, Quera, Rodrigo, Baima, Julio Pinheiro, Saad-Hossne, Rogerio, Sassaki, Ligia Yukie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638044/ https://www.ncbi.nlm.nih.gov/pubmed/34904114 http://dx.doi.org/10.12998/wjcc.v9.i33.10382

Ejemplares similares

Small Intestinal Hemangioma: A Case Report
por: Beraldo, Rodrigo Fedatto, et al.
Publicado: (2021)

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?
por: Beraldo, Rodrigo Fedatto, et al.
Publicado: (2020)

Management of inflammatory bowel disease and serum level of infliximab in newborn exposed to anti-TNF therapy during pregnancy: Case report and literature review
por: de Aragão, Maria Cecília, et al.
Publicado: (2021)

Leukocytoclastic Vasculitis as an Extraintestinal Manifestation of Crohn's Disease
por: Rocha, Thiara Barcelos, et al.
Publicado: (2021)

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report
por: Garate, Ana Lorena Sousa de Vasconcelos, et al.
Publicado: (2021)

MicroRNA expression in inflammatory bowel disease-associated colorectal cancer
por: Grillo, Thais Gagno, et al.
Publicado: (2021)

Immunosuppression and Malignant Neoplasms: Risk-Benefit Assessment in Patients with Inflammatory Bowel Disease
por: Moutinho, Bruna Damásio, et al.
Publicado: (2020)

Anti-TNF Exposure during Pregnancy in Crohn's Disease Patients
por: Silva, Elen Farinelli de Campos, et al.
Publicado: (2018)

Inflammatory bowel disease epidemiology in São Paulo State, Brazil
por: Gasparini, Rodrigo Galhardi, et al.
Publicado: (2018)

Non-Hodgkin's Lymphoma: An Important Differential Diagnosis in Inflammatory Bowel Disease
por: Saad-Hossne, Rogerio, et al.
Publicado: (2018)

COVID-19 in a Patient with Liver Cirrhosis
por: Beraldo, Rodrigo Fedatto, et al.
Publicado: (2021)

Immune Thrombocytopenic Purpura as an Extraintestinal Manifestation in a Patient with Ulcerative Colitis
por: de Medeiros Dutra, Renata, et al.
Publicado: (2022)

Pulmonary Tuberculosis After Therapy with Anti-Tumor Necrosis Factor (TNF) for Crohn Disease: A Case Report
por: da Silva, Douglas Inomata Cardoso, et al.
Publicado: (2021)

Risk factors for ulcerative colitis-associated colorectal cancer: A retrospective cohort study
por: de Campos Silva, Elen Farinelli, et al.
Publicado: (2020)

Intestinal complications in patients with Crohn’s disease in the Brazilian public healthcare system between 2011 and 2020
por: Sassaki, Ligia Yukie, et al.
Publicado: (2023)

Clinical and Psychological Factors Associated with Addiction and Compensatory Use of Facebook Among Patients with Inflammatory Bowel Disease: A Cross-Sectional Study
por: Cury, Giovana Signorelli Astolfi, et al.
Publicado: (2022)

Quality of care in patients with inflammatory bowel disease from a public health center in Brazil
por: Takamune, Debora Mayumi, et al.
Publicado: (2022)

Sexual Dysfunction in Inflammatory Bowel Disease: What the Specialist Should Know and Ask
por: Perez de Arce, Edith, et al.
Publicado: (2021)

Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
por: Grillo, Thais Gagno, et al.
Publicado: (2023)

Herpetic Esophagitis and Eosinophilic Esophagitis: A Potential Association
por: Quera, Rodrigo, et al.
Publicado: (2021)

Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020
por: Martins, Adalberta Lima, et al.
Publicado: (2023)

Gut microbiota, inflammatory bowel disease and colorectal cancer
por: Quaglio, Ana Elisa Valencise, et al.
Publicado: (2022)

Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study
por: de Souza, Letícia Rodrigues, et al.
Publicado: (2023)

Modern surgical strategies for perianal Crohn's disease
por: Zabot, Gilmara Pandolfo, et al.
Publicado: (2020)

Endoscopic Postoperative Recurrence Rates in Crohn's Disease in Korea: The Beginning of a New Approach?
por: Kotze, Paulo Gustavo, et al.
Publicado: (2014)

Escherichia coli from Crohn’s disease patient displays virulence features of enteroinvasive (EIEC), enterohemorragic (EHEC), and enteroaggregative (EAEC) pathotypes
por: da Silva Santos, Ana Carolina, et al.
Publicado: (2015)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Mucosa-associated but not luminal Escherichia coli is augmented in Crohn’s disease and ulcerative colitis
por: de Souza, Helton Luis, et al.
Publicado: (2012)

Fecal microbiota transplantation in refractory ulcerative colitis – a case report
por: Moutinho, B. D., et al.
Publicado: (2019)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

MicroRNAs expression influence in ulcerative colitis and Crohn's disease: A pilot study for the identification of diagnostic biomarkers
por: Quaglio, Ana Elisa Valencise, et al.
Publicado: (2021)

Firearm-Related Musculoskeletal Injuries in Brazilian Children and Teenagers
por: Beraldo, Renato Fedatto, et al.
Publicado: (2019)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn’s Disease
por: de Paula-Silva, Marina, et al.
Publicado: (2021)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_42lt5uok4upqd73q97ok4ok4h3